ISS-HBsAg-Single

ISS-HBsAg-Single refers to a conceptual or experimental therapeutic approach, likely a vaccine or immunotherapy, designed to combat Hepatitis B virus (HBV) infection. It combines an Immunostimulatory Sequence (ISS) with a single component of the Hepatitis B surface antigen (HBsAg). HBsAg is a key viral envelope protein and the primary antigen that elicits immune responses during HBV infection. The 'single' aspect likely indicates the use of a specific HBsAg isoform, such as the small HBsAg (SHB), rather than a multi-antigenic formulation. The Immunostimulatory Sequence, often a CpG oligonucleotide, acts as an adjuvant by activating innate immune receptors like Toll-like receptor 9 (TLR9), thereby enhancing the adaptive immune response to the HBsAg antigen. This combination aims to induce robust humoral and cellular immunity to promote HBsAg seroclearance, a critical endpoint for achieving a functional cure in chronic Hepatitis B.